Innovation Medal in 2022 and is a researcher at the Dynamics of Genetic Information, started the start-up One Biosciences in 2020 as a result of her research. The turn of events in Basic Foundations and the Cancer Laboratory3 One Biosciences is at a crucial moment.
With the first phases of multiple biomedicines scheduled for 2024, we want to increase our visibility at a time when the company is doing more and more. “VivaTech is a key moment for us, when we can present ourselves to investors, institutional actors, and potential business partners,” Magali Richard, the managing director of the company, explains.
One Biosciences hopes to become a global leader in precision medicine for complex diseases by combining “single-cell” technologies with artificial intelligence to discover and develop new therapeutic approaches for precision medicine. The start-up’s single-cell sequencing technologies4 “give access to a treasure trove of information that has never been seen before for the purpose of comprehending the heterogeneity and dynamics of the intricate biological systems underlying pathological mechanisms,” explains Vallot.
The One Biosciences group includes sub-atomic science, mechanical technology, information science, and clinical and modern expertise, all of which are necessary for this development. A component of our competitive advantage is our multidisciplinarity, which has contributed to the development of a number of protocols, tools, and algorithms. The organization’s subsequent stage will be to seek after this thought of development with the objective of consistently further developing our information handling and translation abilities.
